Compare Illumina, Inc. (ILMN) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Workday Inc — how do they compare? Illumina, Inc. trades at $191.73 (market cap $27.94B), while Workday Inc trades at $141.45 (market cap $36.36B). The key difference: Workday Inc is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | WDAY | |
|---|---|---|
Market Cap | $27.94B | $36.36B |
Sector | Health | Technology |
52-Week High | $194.33 | $247.69 |
52-Week Low | $91.00 | $112.55 |
Enterprise Value | $29.33B | $35.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Workday (WDAY) trades at $146.92, up 1.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $151.36. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $2.62. Revenue grew to $8.45 billion in 2025, though net income margin compressed to 6.22% from 19.02% in 2024. Positive sentiment is driven by AI product expansion, but a lawsuit over AI bias and net cash outflows present headwinds.
WDAY offers growth potential with strong subscription revenue and AI-driven deal expansion, yet high P/E of 45.1 suggests premium valuation. Risks include competitive pressures, regulatory scrutiny, and reliance on enterprise spending. Analyst consensus is bullish with 55.55% buy ratings, but investors should monitor execution on profitability and legal challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
